Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker
AbstractClusterin (CLU) has been associated with the clinical progression of Alzheimer’s disease (AD) and described as a potential AD biomarker in blood plasma. Due to the enormous attention given to cerebrospinal fluid (CSF) biomarkers for the past couple of decades, recently found blood-based AD biomarkers like CLU have not yet been reported for biosensors. Herein, we report the electrochemical detection of CLU for the first time using a screen-printed carbon electrode (SPCE) modified with 1-pyrenebutyric acid N-hydroxysuccinimide ester (Pyr-NHS) and decorated with specific anti-CLU antibody fragments. This bifunctional linker molecule contains succinylimide ester to bind protein at one end while its pyrene moiety attaches to the carbon surface by means of π-π stacking. Cyclic voltammetric and square wave voltammetric studies showed the limit of detection down to 1 pg/mL and a linear concentration range of 1–100 pg/mL with good sensitivity. Detection of CLU in spiked human plasma was demonstrated with satisfactory recovery percentages to that of the calibration data. The proposed method facilitates the cost-effective and viable production of label-free point-of-care devices for the clinical diagnosis of AD. View Full-Text
Share & Cite This Article
Islam, K.; Damiati, S.; Sethi, J.; Suhail, A.; Pan, G. Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker. Sensors 2018, 18, 308.
Islam K, Damiati S, Sethi J, Suhail A, Pan G. Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker. Sensors. 2018; 18(1):308.Chicago/Turabian Style
Islam, Kamrul; Damiati, Samar; Sethi, Jagriti; Suhail, Ahmed; Pan, Genhua. 2018. "Development of a Label-Free Immunosensor for Clusterin Detection as an Alzheimer’s Biomarker." Sensors 18, no. 1: 308.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.